Monthly triple-dose gadolinium administration: potential associations with leukopenia, hypophosphatemia, and bone marrow T1 hyperintensity.

Daniel ChenIvan WolanskyJaime ImitolaCarl MalchoffRong WuSuhayl Dhib-JalbutKetan BulsaraLeo Wolansky

Published in: The Journal of international medical research (2022)

Although monthly administration of triple-dose gadopentetate dimeglumine over 13 months has been associated with progressive increases in leukopenia, hypophosphatemia, and T1 signal intensity of bone, this study showed an inverse relationship between leukopenia and hypophosphatemia.

Keyphrases

bone marrow
multiple sclerosis
mesenchymal stem cells
bone mineral density
high intensity
magnetic resonance imaging
computed tomography
human health
bone loss